Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Other Accumulated Expenses (2016 - 2021)

Corbus Pharmaceuticals Holdings has reported Other Accumulated Expenses over the past 8 years, most recently at $1.7 million for Q4 2021.

  • For Q4 2021, Other Accumulated Expenses rose 19.02% year-over-year to $1.7 million; the TTM value through Dec 2021 reached $1.7 million, up 19.02%, while the annual FY2021 figure was $1.7 million, 19.02% up from the prior year.
  • Other Accumulated Expenses for Q4 2021 was $1.7 million at Corbus Pharmaceuticals Holdings, up from $1.4 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $1.7 million in Q4 2021 and troughed at $110446.0 in Q2 2017.
  • A 5-year average of $921957.2 and a median of $953206.0 in 2019 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 440.34% in 2019 and later dropped 16.06% in 2021.
  • Year by year, Other Accumulated Expenses stood at $146609.0 in 2017, then skyrocketed by 214.17% to $460596.0 in 2018, then soared by 108.19% to $958928.0 in 2019, then soared by 52.35% to $1.5 million in 2020, then grew by 19.02% to $1.7 million in 2021.
  • Business Quant data shows Other Accumulated Expenses for CRBP at $1.7 million in Q4 2021, $1.4 million in Q3 2021, and $1.5 million in Q2 2021.